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Genome-wide association study of 23,500
individuals identiﬁes 7 loci associated with brain
ventricular volume
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The volume of the lateral ventricles (LV) increases with age and their abnormal enlargement
is a key feature of several neurological and psychiatric diseases. Although lateral ventricular
volume is heritable, a comprehensive investigation of its genetic determinants is lacking. In
this meta-analysis of genome-wide association studies of 23,533 healthy middle-aged to
elderly individuals from 26 population-based cohorts, we identify 7 genetic loci associated
with LV volume. These loci map to chromosomes 3q28, 7p22.3, 10p12.31, 11q23.1, 12q23.3,
16q24.2, and 22q13.1 and implicate pathways related to tau pathology, S1P signaling, and
cytoskeleton organization. We also report a signiﬁcant genetic overlap between the thalamus
and LV volumes (ρgenetic=−0.59, p-value= 3.14 × 10−6), suggesting that these brain
structures may share a common biology. These genetic associations of LV volume provide
insights into brain morphology.
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The volume of lateral ventricles increases in normalaging1–4. The enlargement of lateral ventricles has alsobeen suggested in various complex neurological disorders
such as Alzheimer’s disease, vascular dementia, and Parkinson’s
disease5–8 as well as psychiatric disorders such as schizophrenia
and bipolar disorder9–11. Furthermore, ventricular enlargement
has been associated with poor cognitive functioning and cerebral
small vessel disease pathology12–14. Even though it might be
intuitive to interpret ventricular expansion primarily as an indi-
cator of brain shrinkage after the onset of the disorder, recent
studies have provided evidence against this notion15,16. The size
of lateral ventricles is inﬂuenced by genetic factors with herit-
ability estimated to be 54%, on average16, but changing with age,
from 32–35% in childhood to about 75% in late middle and older
age16. Even though the size of surrounding gray matter structures
is also heritable17–19, ventricular volume is reported to be
genetically independent of other brain regions surrounding the
ventricles20. Similarly, ventricular enlargement in schizophrenia
does not appear to be linked to volume reduction in the sur-
rounding structures15.
Elucidating the genetic contribution to inter-individual varia-
tion in lateral ventricular volume can thus provide important
insights and better understanding of the complex genetic archi-
tecture of brain structures and related neurological and psychia-
tric disorders. Candidate gene studies have identiﬁed single-
nucleotide polymorphisms (SNPs) mapping to Catechol-O-
Methyltransferase (COMT) and Neuregulin 1 (NRG1) genes as
associated with larger lateral ventricular volume in patients with
the ﬁrst episode of non-affective psychosis21,22. However, a
comprehensive investigation of the genetic determinants of lateral
ventricular volume is lacking.
Here, we perform a genome-wide association (GWA) meta-
analysis of 23,533 middle-aged to elderly individuals from
population-based cohorts participating in the Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE)
consortium in order to identify common genetic variants that
inﬂuence lateral ventricle volume. We apply a commonly used
two-stage GWA design followed by a joint analysis approach that
combines information across the stages and provides greater
power23. We identify 7 genetic loci associated with lateral ven-
tricular volume and report genome-wide overlap with thalamus
volume.
Results
Genome-wide association results. The overview of study design
is illustrated in Supplementary Fig. 1. The GWA results from
12 studies were combined in stage 1 and subsequently evaluated
in an independent sample from 14 studies in stage 2. Finally, the
results of stage 1 and stage 2 analyses were combined in stage 3.
Detailed information on study participants, image acquisition and
genotyping is provided in Supplementary Note 1 and Supple-
mentary Data 1–3.
The results of the stage 1 meta-analysis (N= 11,396) are
illustrated in Supplementary Fig. 2. The quantile-quantile plot
suggests that potential population stratiﬁcation and/or cryptic
relatedness are well controlled after genomic correction (λ= 1.04)
(Supplementary Fig. 2, Supplementary Table 1). The stage 1 meta-
analysis identiﬁed 146 signiﬁcant variant associations, mapping to
three chromosomal regions at 3q28, 7p22.3, and 16q24.2 (Table 1).
All 146 stage 1 signiﬁcant associations replicated in the stage 2
meta-analysis (N= 12,137) with the same direction of effect at
Bonferroni adjusted signiﬁcance (p-value= 5 × 10−3, Supplemen-
tary Data 4), except one SNP (p-value= 7.6 × 10−3). Subsequently,
the results from all individual studies were combined in the stage 3
GWA meta-analysis (N= 23,533). The quantile–quantile plot
showed again adequate control of population stratiﬁcation or
relatedness (Supplementary Fig. 3). The combined stage 3 GWA
meta-analysis identiﬁed 314 additional signiﬁcant associations
mapping to four additional chromosomal regions at 10p12.31,
11q23.1, 12q23.3, and 22q13.1 (Figs. 1, 2, Table 1). The effect size
for the lead variant mapped to 10p12.31 locus was correlated with
mean age of the cohort (r= 0.50, p-value= 0.03) (Supplementary
Fig. 4). No correlation was found for the other lead variants
(Supplementary Fig. 5–10).
Even though cohorts of European (EA) and African-American
(AA) ancestry were included, all signiﬁcant associations were
mainly driven by EA samples (Supplementary Fig. 11–12). The
direction of effect size across the EA cohorts for the seven lead
variants was generally concordant and showed no evidence of any
single cohort driving the associations (Supplementary Fig. 11).
Despite the different methods of phenotyping across the cohorts,
the cohorts with different phenotyping methods showed evidence
of effect suggesting that there is limited heterogeneity in effects
(Supplementary Fig. 12).
To investigate whether seven lead variants have an effect in
early life, childhood, the analyses were carried out in a children’s
cohort of 1141 participants from Generation R study. The
percentage of lead variants showing consistent direction of effect
with stage 3 was 85.7% (6 out of 7, binomial p-value= 0.05)
(Supplementary Data 4), and a variant mapped to the 12q23.3
region showed nominal association with lateral ventricular
volume in the children’s cohort (Zscore = −2.56, p-value=
0.01). Additionally, three out of seven lead variants (or their
proxies; r2 > 0.7) showed pleiotropic association (p-value < 5 ×
10−8) with other traits according to the PhenoScanner database
(Supplementary Data 5)24.
To capture gender-based differences, sex-stratiﬁed GWA
analysis was performed (Nmen= 10,358; Nwomen= 12,872).
None of the 15,660,719 variants that were tested for heterogeneity
between men and women reached genome-wide signiﬁcance
threshold (Supplementary Fig. 13). However, an indel located at
4q35.2 showed suggestive evidence of association in men
(4:187559262:C_CAA, p-value= 5.43 × 10−8) but not in women
(p-value= 0.88).
Independent signals within loci. The conditional and joint
(COJO) analysis using the Genome-wide Complex Trait Analysis
(GCTA) identiﬁed no other additional variants, after condition-
ing on the lead variant at the locus 3q28, 7p22.3, 10p12.31,
11q23.1, 12q23.3, 16q24.2, or 22q13.1.
Functional annotation. A large proportion of genome-wide
signiﬁcant variants were intergenic (335/460) (Supplementary
Fig. 14). Variants with the highest probability of having a reg-
ulatory function based on RegulomeDB score (Category 1 Reg-
ulomeDB score) were located at 7p22.3 and at 22q13.1
(Supplementary Data 6). Of seven lead variants, four were
intergenic, four were in an active chromatin state and three
showed expression quantitative trait (eQTL) effects (Supple-
mentary Data 6). The lead SNP at 22q13.1 (rs4820299) was
associated with differential expression of the largest number of
genes (n= 6). In brain tissue, the alternate allele of this SNP was
associated with higher expression of TRIOBP suggesting that
higher expression was associated with smaller lateral ventricles
(Supplementary Fig. 15).
Partitioned heritability. SNP-based heritability in the sample of
European ancestry participants was estimated at 0.20 (SE= 0.02)
using LD score regression, and this was higher in women 0.19
(SE= 0.04) than in men 0.15 (SE= 0.05). The seven lead variants
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explained 1.5% of total variance in lateral ventricular volume.
Partitioning of heritability based on functional annotation using LD
score regression, revealed signiﬁcant enrichment of SNPs within
500 bp of highly active enhancers, where 17% of SNPs accounted
for 54% of the heritability (p-value= 7.9 × 10−6, Supplementary
Table 2). Signiﬁcant enrichment was also found for histone marks
including H3K27ac (which indicates enhancer and promoter
regions), H3K9ac (which highlights promoters), H3K4me3 (which
indicates promoters/transcription starts), and H3K4me1 (which
highlights enhancers) (Supplementary Table 2)25,26.
Functional enrichment analysis. Functional enrichment analysis
using regulatory regions from the ENCODE and Roadmap pro-
jects using the GWAS Analysis of Regulatory or Functional
Information Enrichment with LD correction (GARFIELD)
method revealed that SNPs associated with lateral ventricular
volume at p-value threshold <10−5 were more often located in
genomic regions harboring histone marks (H3K9ac (associated
with promoters) and H3K36me3 (associated with transcribed
regions))25 and DNaseI hypersensitivity sites (DHS) than a per-
muted background (Fig. 3, Supplementary Data 7).
Integration of gene expression data. Integration of functional
data from the Genotype-Tissues Expression (GTEx) project using
the MetaXcan method revealed two signiﬁcant associations
between genetically predicted expression in brain tissue and lat-
eral ventricular volume (Supplementary Fig. 16). Expression
levels of TRIOBP at the locus 22q13.1 (p-value= 3.2 × 10−6) and
MRPS16 at the locus 10q22.2 (p-value= 1.8 × 10−6) were asso-
ciated with lateral ventricular volume.
Gene annotation and pathway analysis. The results of gene-
based and pathway analyses are illustrated in Supplementary
Table 3 and Supplementary Data 8. The pathway analysis
identiﬁed “regulation of cytoskeleton organization”
(GO:0051493) gene-set to be signiﬁcantly enriched (p-value=
6 × 10−6). Genes of the “regulation of cytoskeleton organization”
pathway have previously been implicated in various neurological
or cardiovascular diseases (Supplementary Data 9). Furthermore,
pathways that pointed towards sphingosine 1 phosphate (S1P)
signaling showed suggestive enrichment (Supplementary Data 8).
Genetic correlation. Additionally, we examined the genetic
overlap between lateral ventricular volume and other traits
(Table 2). We found that genetically determined components of
thalamus and lateral ventricular volumes appear to be negatively
correlated (ρgenetic=−0.59, p-value= 3.14 × 10−6). This ﬁnding
was also conﬁrmed at the phenotype level (Supplementary
Table 4). Weaker genetic overlap was observed with infant head
circumference (ρgenetic= 0.28, p-value= 8.7 × 10−3), intracranial
volume (ρgenetic= 0.35, p-value= 9 × 10−3), height (ρgenetic=
−0.14, p-value= 5.7 × 10−3), and mean pallidum (ρgenetic=
−0.29, p-value= 2.5 × 10−2), whereas no signiﬁcant genetic
overlap was found with neurological diseases, psychiatric diseases,
or personality traits.
Genetic risk score. We next examined the association of genetic
risk scores (GRS) for Alzheimer’s disease, Parkinson’s disease,
schizophrenia, bipolar disorder, cerebral small vessel disease, and
tau-related pathology, including tau and phosphorylated tau
levels in cerebrospinal ﬂuid, amyotrophic lateral sclerosis (ALS),
and progressive supranuclear palsy (PSP), using the lead SNPs
from the largest published GWA study and lateral ventricular
volume (Supplementary Data 10). We found a suggestive asso-
ciation of GRS for tau levels in cerebrospinal ﬂuid (p-value=
9.59 × 10−3) and lateral ventricular volume (Supplementary
Table 5). The association was driven by one SNP (Supplementary
Table 1 Genome-wide signiﬁcant results from the meta-analyses of lateral ventricular volume
SNP Chr Annotation Gene(s) A1/A2 Stage 1 Stage 2 Stage 3 combined
Zscore P Zscore P Zscore P
rs34113929a 3q28 intergenic SNAR-I,OSTN A/G −6.84 7.70E−12 −5.05 4.44E−07 −8.27 1.37E−16
rs9937293a 16q24.2 intergenic FOXL1,C16orf95 A/G 5.65 1.63E−08 5.61 2.03E−08 7.84 4.45E−15
7:2760334:C_CTa 7p22.3 intergenic AMZ1,GNA12 D/I −5.88 4.21E−09 −4.48 7.34E−06 −7.21 5.61E−13
rs12146713 12q23.3 intronic NUAK1 T/C −5.01 5.57E−07 −5.44 5.32E−08 −7.28 3.25E−13
rs4820299 22q13.1 intronic TRIOBP T/C −4.79 1.71E−06 -4.49 7.04E−06 −6.46 1.05E−10
rs35587371 10p12.31 intronic MLLT10 A/T −4.89 1.03E−06 −3.32 9.12E−04 −5.61 2.07E−08
rs7936534 11q23.1 intergenic ARHGAP20,C11orf53 A/G 4.25 2.12E−05 3.71 2.04E−04 5.54 2.96E−08
Variant that showed the lowest p-value in the ﬁxed effect sample-size weighted Z-score meta-analysis for each locus is shown
SNP: single-nucleotide polymorphism, Chr: chromosome, A1/A2: effect allele/other allele, Freq: frequency of effect allele, Zscore: Z score from METAL, P: p-value
aVariants that surpassed genome-wide signiﬁcance threshold in stage 1 meta-analysis; remaining SNPs listed in the table reached genome-wide signiﬁcance threshold in combined, stage 3, meta-analysis
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Table 6). No association was observed with other examined
phenotypes (Supplementary Table 5).
Discussion
We have performed the ﬁrst genome-wide association study of
lateral ventricular volume including up to 23,533 individuals. We
identiﬁed statistically signiﬁcant association between lateral ven-
tricular volume and variants at 7 loci. Additionally, we found that
genetically determined components of thalamus and lateral ven-
tricular volume are correlated.
The strongest association was observed at the intergenic 3q28
locus between non-coding RNA SNAR-I and OSTN. This region
has previously been associated with cerebrospinal ﬂuid tau/ptau
levels and Alzheimer’s disease risk, tangle pathology and cognitive
decline27. Similarly, the genome-wide signiﬁcant locus at 12q23.3
encompasses NUAK1, which has also been associated with tau
pathology. Nuak1 modulates tau levels in human cells and animal
models and associates with tau accumulation in different tauo-
pathies28. NUAK1 is most prominently expressed in the brain
where it has a role in mediating axon growth and branching in
cortical neurons29. The lead SNP of the 12q23.3 locus mapped to
an intron of NUAK1. This SNP is among the top 1% of most
deleterious variants in the human genome based on its Combined
Annotation Dependent Depletion (CADD) score of 21.5 and is
located in an enhancer region (Supplementary Data 6). Interest-
ingly, this variant also showed an effect in early life.
In our data, the signiﬁcant variants of 7p22.3 region had the
highest probability of being regulatory based on the RegulomeDB
score (1b). The lead variant at 7p22.3 was in an active chromatin
state and was associated with differential expression of GNA12
(Supplementary Data 6). The GNA12 gene is involved in various
transmembrane signaling systems30–33. Interestingly, this gene was
part of S1P signaling pathways identiﬁed to be enriched among
genes associated with lateral ventricular volume. S1P, a bioactive
sphingolipid metabolite, regulates nervous system development34
such as neuronal survival, neurite outgrowth, and axon
guidance35,36, and plays a role in neurotransmitter release37. It also
plays a role in regulating the development of germinal matrix (GM)
vasculature38. Disruption of S1P regulation results in defective
angiogenesis in GM, hemorrhage, and enlarged ventricles38.
The other identiﬁed locus, 16q24.2, has previously been
connected with small vessel disease and white-matter lesions
formation39. Further, the alternate allele of the lead SNP at
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Fig. 2 Regional association and recombination plots in combined stage 3 GWA meta-analysis. The left axis represents –log10 p-values for association with
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22q13.1 in TRIOBP is associated with higher expression of the
same gene in basal ganglia and brain cortex, and the same allele
is associated with smaller lateral ventricular volume. Interest-
ingly, predicted expression of this gene in cerebral cortex was
signiﬁcantly associated with lateral ventricular volume, sug-
gesting a causal functional role of the gene. The same analysis
revealed signiﬁcant association of the expression of MRPS16 in
frontal cortex with lateral ventricular volume. This gene was
previously related to agenesis/hypoplasia of corpus callosum
and enlarged ventricles40.
Finally, the lead intergenic SNP at 11q23.1 maps between
C11orf53 and ARHGAP20, whereas the 10p12.31 region encom-
passes MLLT10 which has been linked to various leukemias,
ovarian cancer, and meningioma41,42. The effect size of this
variant on lateral ventricular volume was correlated with mean
cohort age, with the effect being near zero at younger age and
larger at older ages.
The gene-enrichment analysis highlighted “regulation of
cytoskeleton organization” (GO:0051493) pathway. Genes that
are part of this pathway have previously been implicated in
various neurological diseases such as Parkinson’s disease
(PARK2), frontotemporal dementia (MAPT), neuroﬁbromatosis 2
(NF2), tuberous sclerosis (TSC1) (Supplementary Data 9). The
cytoskeleton is essentially involved in all cellular processes, and
therefore crucial for processes in the brain such as cell pro-
liferation, differentiation, migration, and signaling. Dysfunction
of cytoskeleton has been associated with neurodevelopmental,
psychiatric and neurodegenerative diseases43–45.
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Previous studies showed signiﬁcant sex-speciﬁc differences in
lateral ventricular volume46,47. In our study we did not observe
sex-speciﬁc differences; as for the lead seven variants, both males
and females were contributing to the association signal. However,
we observed only one suggestive association at 4q35.2 that
showed association in men only. The lead variant (indel) is
mapped to FAT1 which encodes atypical cadherins. Mutation in
this gene causes a defect in cranial neural tube closure in a mouse
model and an increase in radial precursor proliferation in the
cortex48. However, the SNP-based heritability estimates were
slightly higher in females. This may be explained by the differ-
ences in sample size in male and female-speciﬁc analyses
implying that there is lower precision.
We estimated that 20% of genetic variance in lateral ven-
tricular volume could be explained by common genetic var-
iants, suggesting that common variants represent a substantial
fraction of overall genetic component of variance. Moreover,
the most statistically signiﬁcant effect occurred in the regions of
highly active enhancers and histone marks, suggesting their
involvement in gene expression. Using the LD score regression
method, we found a signiﬁcant negative genetic correlation
between lateral ventricular volume and thalamus volume.
However, these may not be independent events, but inverse
reﬂections of the same biology. Even though not strictly sig-
niﬁcant, we also observed trends for genetic correlations with
other brain volumetric measures. Furthermore, no genome-
wide overlap was found between lateral ventricular volume and
various neurological or psychiatric diseases. Given that enlar-
gement of lateral ventricles has been suggested in Alzheimer’s
disease, we examined the association of APOE alleles and found
no association between the APOE ɛ4 (p-value= 0.86) or APOE
ɛ2 (p-value= 0.81) and lateral ventricular volume in our study
population.
As we identiﬁed loci underlying lateral ventricular volume at
the genome-wide level, but also genes and common pathways,
our results provide various insights into the genetic contribution
to lateral ventricular volume variability and a better under-
standing of the complex genetic architecture of brain structures.
The genes with variants that we found to be associated with
lateral ventricular volume are relevant to neurological aging
given the characteristics of the study population which is rela-
tively free from the disease as participants with stroke, traumatic
brain injury and dementia at the time of magnetic resonance
imaging (MRI) were excluded. This is in line with the previously
published work of Pfefferbaum et al. who showed that the sta-
bility of lateral ventricles is genetically determined, whereas other
factors such as normal aging or trauma and disease play a role in
its change1,16.
However, while studying genetic overlap of lateral ventricular
volume and various neurological or psychiatric disorders at
Table 2 The results of genetic correlation between the lateral ventricular volume and anthropometric traits, brain volumes,
neurological and psychiatric diseases and personality traits
Category Phenotype PMID N rg SE P
Anthropometric
Height 20881960 133,859 −0.135 0.049 5.70E−03
Infant head circumference 22504419 10,768 0.284 0.108 8.70E−03
Child birth length 25281659 28,459 −0.133 0.089 1.34E−01
Child birth weight 23202124 26,836 −0.118 0.102 2.47E−01
Brain volume
Mean thalamus 25607358 13,193 −0.591 0.127 3.14E−06
Mean pallidum 25607358 13,142 −0.29 0.129 2.47E−02
ICV 25607358 11,373 0.347 0.133 9.00E−03
Mean accumbens 25607358 13,112 −0.29 0.158 6.64E−02
Mean putamen 25607358 13,145 −0.15 0.089 9.13E−02
Mean hippocampus 25607358 13,163 −0.204 0.132 1.20E−01
Mean caudate 25607358 13,171 0.012 0.105 9.06E−01
Neurological diseases
Alzheimer’s disease 24162737 54,162 0.181 0.11 9.87E−02
Parkinson’s disease 19915575 5691 −0.096 0.084 2.55E−01
Amyotrophic lateral sclerosis 27455348 36,052 −0.032 0.128 8.04E−01
White matter hyperintensities 25663218 17,940 0.100 0.094 2.87E−01
Personality traits
Neo-conscientiousness 21173776 17,375 −0.359 0.158 2.27E−02
Neo-openness to experience 21173776 17,375 0.088 0.118 4.56E−01
Neuroticism 27089181 170,911 −0.03 0.065 6.45E−01
Psychiatric traits
ADHD 20732625 5422 −0.276 0.152 6.90E−02
PGC cross-disorder analysis 23453885 61,220 −0.121 0.071 8.65E−02
Major depressive disorder 22472876 18,759 −0.165 0.102 1.05E−01
Schizophrenia 25056061 77,096 −0.067 0.044 1.30E−01
Subjective well-being 27089181 298,420 0.087 0.075 2.50E−01
ADHD (no GC) 27663945 17,666 −0.151 0.149 3.11E−01
Depressive symptoms 27089181 161,460 −0.038 0.071 5.93E−01
Autism spectrum disorder 0 10,263 0.041 0.092 6.53E−01
Anorexia nervosa 24514567 17,767 0.011 0.056 8.43E−01
Bipolar disorder 21926972 16,731 0.009 0.078 9.12E−01
rg: genetic correlation, SE: standard error, P: p-value
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multiple levels (LD score regression/polygenic, GRS/oligogenic,
GWA hits/monogenic), we found evidence that some single
genetic variants have pleiotropic effect on lateral ventricular
volume and biochemical markers for a neurological disease (AD)
or meningioma (Supplementary Data 5), while no evidence was
found for genetic overlap with other neurological or psychiatric
disorders (Table 2, Supplementary Table 5). The pattern of
association between lateral ventricular volume and psychiatric
disorder, i.e., schizophrenia on multiple scales is similar to the
ﬁndings of Franke et al. who evaluated association of various
subcortical brain volumes and schizophrenia and reported no
evidence of genetic overlap49. Even though our study does not
provide a deﬁnite statement regarding the relationship between
lateral ventricular volume and neurological or psychiatric dis-
orders, it lays the foundation for future studies which should
disentangle whether lateral ventricular volume is genetically
related or unrelated to various neurological and psychiatric dis-
orders (e.g., result from reverse causation). Novel insights may be
revealed by improving the power of the studies, studying
homogeneous samples with harmonized phenotype assessment
methods along with evaluation of common and rare variants.
The strengths of our study are the large sample, population-
based design and the use of quantitative MRI. Our study also has
several limitations. Despite the effort to harmonize phenotype
assessment, the methods used to quantify lateral ventricular
volume differ across cohorts. Because of this phenotypic hetero-
geneity, association results of participating cohorts were com-
bined using a sample-size weighted meta-analysis, thus limiting
discussion on effect sizes. Secondly, phenotypic heterogeneity
may have caused the loss of statistical power. However, despite
heterogeneity in the phenotype assessment, the association signals
were coming from several studies irrespective of the method of
phenotype assessment, which suggests robustness of our ﬁndings.
Furthermore, although we made an effort to include cohorts of
EA and AA ancestry, the study comprised predominately of
individuals of European origin (22,045 individuals of EA and
1488 of AA ancestry). Given the disparity in sample size, it is
difﬁcult to distinguish whether any inconsistency in results
between the two groups stems from true genetic differences or
from differential power to detect genetic effects. Indeed, this is
also exempliﬁed by the plots of the Z-scores (Supplementary
Fig. 11) showing that direction of effect size in AA cohorts is
often inconsistent with the direction of effect size in EA cohorts.
However, the same inconsistency can be observed with European
cohorts of equally small sample size. This inconsistency may be
due to small sample size rather than ethnic background but we
cannot rule out that racial-ethnic speciﬁc effects may exit. This
limitation underscores the need for expanding research studies in
non-European populations. Finally, as some loci only reached the
genome-wide signiﬁcance in the combined meta-analysis, they
should be considered as highly probable ﬁndings and would still
require independent replication.
To conclude, we identiﬁed genetic associations of lateral ven-
tricular volume with variants mapping to 7 loci and implicating
several pathways, including pathway related to tau pathology,
cytoskeleton organization, and S1P signaling. These data provide
new insights into understanding brain morphology.
Methods
Study design. The overview of study design is illustrated in Supplementary Fig. 1.
We performed a GWA meta-analysis of 11,396 participants of mainly European
ancestry from 12 studies (stage 1) that contributed summary statistic data before a
certain deadline. The deadline was set prior to data inspection and was not
inﬂuenced by the results of the GWA meta-analysis. Variants that surpassed the
genome-wide signiﬁcance threshold (p-value < 5 × 10−8) were subsequently eval-
uated in an independent sample of 12,137 participants of mainly European
ancestry from 14 studies (stage 2). Finally, we performed a meta-analysis of all
stage 1 and stage 2 studies (stage 3).
Study population. All participating studies are part of the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium50. A detailed
description of participating studies can be found in Supplementary Note 1. General
characteristics of study participants are provided in Supplementary Data 1. Written
informed consent was obtained from all participants. Each study was approved by
local ethical committees or the institutional review boards (see Supplementary
Note 1 for details).
Imaging. Each study performed MRI and estimated the volume of the lateral
ventricles and intracranial volume (ICV). The ﬁeld strength of scanners ranged
from 0.35 to 3 T. Information on scanner manufacturers and measurement
methods is provided in Supplementary Data 2. While most of the studies quantiﬁed
lateral ventricular volume using validated automated segmentation methods, some
studies used validated visual grading scales. The visual and volumetric scales were
compared previously and showed high agreement for lateral ventricular volume2.
The assessment of consistency of lateral ventricular volume on volumetric scale
across time and different versions of software (freesurfer v4.5, v5.1, and v6.0),
revealed high intraclass correlation (ICC > 0.98) in a subset of participants from the
Rotterdam Study. Participants with dementia at the time of MRI, traumatic brain
injury, prior or current stroke or intracranial tumors were excluded.
Genotyping and imputation. Information on genotyping platforms, quality con-
trol procedures and imputations methods for each participating study are provided
in Supplementary Data 3. All studies used commercially available genotyping
arrays, including Illumina or Affymetrix arrays. Similar quality control procedures
were applied for each study (Supplementary Data 3). Using the validated software
(Minimac51, IMPUTE52, BEAGLE53), each study performed genotype imputations
using mostly the 1000 Genome phase 1 v3 reference panel.
Genome-wide association (GWA) analysis. Each participating study performed
the GWA analysis of total lateral ventricular volume under an additive model
using variant allele dosage as predictors and natural logarithm of the total lateral
ventricular volume as the dependent variable. Transformation of the lateral
ventricular volume was applied to obtain approximately normal distribution
(Supplementary Fig. 17). The association analyses were adjusted for age, sex,
total intracranial volume, age2 if signiﬁcant, population stratiﬁcation, familial
relationship (family-based studies) or study site (multi-site studies). Population
stratiﬁcation was controlled for by including principal components derived from
genome-wide genotype data. Study-speciﬁc details on covariates and software
used are provided in Supplementary Data 3. Quality control (QC) was conducted
for all participating studies using a standardized protocol provided by Winkler
et al.54. Variants with low imputation quality r2 < 0.3 or minor allele count
(MAC) ≤ 6 were ﬁltered out. The association results of participating studies were
combined using a ﬁxed-effect sample-size weighted Z-score meta-analysis in
METAL because of the difference in measurement methods of lateral ventricular
volume55. Genomic control was applied to account for small amounts of
population stratiﬁcation or unaccounted relatedness. After the meta-analysis,
variants with information in less than half the total sample size were excluded.
Meta-analyses were performed separately for each of the stages. In the stage 1
meta-analysis, a p-value < 5 × 10−8 was considered signiﬁcant. Variants that
surpassed the threshold were evaluated in the stage 2 meta-analysis. In order to
model linkage disequilibrium (LD) between those variants, we ﬁrst calculated the
number of independent tests using the eigenvalues of a correlation matrix using
the Matrix Spectral Decomposition (matSpDlite) software56. Subsequently, a
Bonferroni correction was applied for the effective number of independent tests
(0.05/10 independent SNPs= 5 × 10−3). Additionally, all analyses were stratiﬁed
by sex. Following the same QC steps as for overall analyses, the sex-stratiﬁed
association results of participating studies were combined using a ﬁxed-effect
sample-size weighted Z-score meta-analysis in METAL while applying genomic
control55. The variants were assessed only if test statistics (Z-score) were het-
erogeneous between males and females (p-value < 0.1) and if the association in a
sex-combined analysis did not reach genome-wide signiﬁcance threshold57.
Conditional analysis. In order to identify variants that were independently asso-
ciated with lateral ventricular volume, we performed conditional and joint (COJO)
GWA analysis using Genome-wide Complex Trait Analysis (GCTA), version
1.26.058. LD pattern was calculated based on 1000 Genome phase 1v3 imputed data
of 6291 individuals from the Rotterdam Study I.
Functional annotation. To annotate genome-wide signiﬁcant variants with reg-
ulatory information, we used HaploReg v4.159, RegulomeDB v1.160, and Combined
Annotation Dependent Depletion (CADD) tools61. To determine whether they
have an effect on gene expression, we used GTEx data62. For the lead variants, we
explored 5 chromatin marks assayed in 127 epigenomes (H3K4me3, H3K4me1,
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H3K36me3, H3K27me3, H3K9me3) of RoadMap data63. To search for pleiotropic
associations between our lead variants and their proxies (r2 > 0.7) with other traits,
we used the PhenoScanner database designed to facilitate the cross-referencing of
genetic variants with many phenotypes9. The association results with genome-wide
signiﬁcance at 5 × 10−8 were extracted.
Variance explained. The proportion of variance in lateral ventricular volume
explained by each lead variant was calculated using Pearson’s phi coefﬁcient
squared as explained in Draisma et al.64. The total proportion of variance in lateral
ventricular volume was calculated by adding up the proportions of variance in
lateral ventricular volume explained by each lead association signal.
Partitioned heritability. SNP-based heritability and partitioned heritability ana-
lyses were performed using LD score regression following the previously described
method65. Partitioned heritability analysis determines enrichment of heritability in
SNPs partitioned into 24 functional classes as reported in Finucane et al.65. To
avoid bias, an additional 500 bp window was included around the variants included
in the functional classes. Only the HapMap3 variants were included as these seem
to be well-imputed across cohorts.
Functional enrichment analysis. We performed functional enrichment analysis
using regulatory regions from the ENCODE and Roadmap projects using GWAS
Analysis of Regulatory or Functional Information Enrichment with LD correction
(GARFIELD) method66. The method provides fold enrichment (FE) statistics at
various GWA p-value thresholds after taking into account LD, minor allele fre-
quency, and local gene density66. The FE statistics were calculated at eight GWA
p-value thresholds (0.1 to 1 × 10−8). The associations were tested for various reg-
ulatory elements including DNase-I hypersensitivity sites, histone modiﬁcations,
chromatin states and transcription factor binding sites in over 1000 cell and tissue-
speciﬁc annotations66. The signiﬁcance threshold calculated based on the number
of annotations used was set at 4.97 × 10−5.
Integration of gene expression. To integrate functional data in the context of our
meta-analysis results, we used the MetaXcan method, which evaluated the asso-
ciation between lateral ventricular volume and brain-speciﬁc gene-expression levels
predicted by genetic variants using the data from GTEx project62,67. This method is
an extension of PrediXcan method modiﬁed to use summary statistic data from
meta-analysis67. Based on a total number of genes tested, the Bonferroni-corrected
signiﬁcance threshold was set to 0.05/12,379= 4 × 10−6.
Gene annotation and pathway-based analysis. The gene-based test statistics
were computed using VEGAS2 software which tests for enrichment of multiple
single variants within the genes while accounting for LD structure68. LD structure
was computed based on the 1000 Genomes phase 3 population. Variants within
10 kb of the 5′ and 3′ untranslated regions were included in this analysis in order to
maintain regulatory variants68. Subsequently, the gene-based scores were used to
perform gene-set enrichment analysis using VEGAS2pathway69. VEGAS2Pathway
approach accounts for LD between variants within a gene, and between neigh-
boring genes, gene size, and pathway size69. It uses computationally predicted Gene
Ontology pathways and curated gene-sets from the MSigDB, PANTHER, and
pathway commons databases69. The pathway-based signiﬁcance threshold was set
to the p-value= 1 × 10−5 while taking into account the multiple testing of corre-
lated pathways (0.05/5000 independent tests)69.
Genetic correlation. We used the LD score regression method to estimate genetic
correlations between lateral ventricular volume and various traits including
anthropometric traits, brain volumes, neurological and psychiatric diseases and
personality traits. The analyses were performed using a centralized database of
summary-level GWA study results and a web interface for LD score regression, the
LD-hub70. Summary-level GWA study results for white matter hyperintensities
were obtained from the CHARGE consortium71 and the analyses were performed
using the ldsc tool (https://github.com/bulik/ldsc).
Genetic risk scores. We generated genetic risk scores (GRS) for Alzheimer’s
disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, bipolar dis-
order, schizophrenia, white matter lesions and tau-related phenotypes. The tau-
related phenotypes, including tau and phosphorylated tau levels in cerebrospinal
ﬂuid, and progressive supranuclear palsy (PSP), were studied in relatively small
sample and are therefore not appropriate for LD score regression. We extracted
the lead genome-wide signiﬁcantly associated SNPs and their effect estimates
from the largest published GWA studies (Supplementary Data 10). For white
matter lesions burden, effect estimate and standard errors were estimated from
Z-statistics using the previously published formula72. The allele associated with
an increased risk in corresponding traits was considered to be the effect allele.
The weighted GRS was constructed as the sum of products of effect sizes as
weights and respective allele dosages from 1000 Genome imputed data of Rot-
terdam Study using R software version 3.2.5 (https://www.R-project.org). Var-
iants with low imputation quality (r2 < 0.3) were excluded. Subsequently, the
GRS was tested for association with lateral ventricular volume in three cohorts of
Rotterdam Study while adjusting for age, sex, total intracranial volume, age2 and
population stratiﬁcation. The signiﬁcance threshold for genetic risk score
association was set to p-value= 5 × 10−3 (0.05/10) based on the number of
genetic risk scores tested.
Data availability
The summary statistics will be made available upon publication on the CHARGE dbGaP
site under the accession number phs000930.v7.p1.
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